Ambrisentan received initial approval from the U.S. Food and Drug Administration (FDA) on June 15, 2007, for treating pulmonary arterial hypertension (PAH).

Ambrisentan is used to treat pulmonary arterial hypertension (PAH). PAH is characterized by high blood pressure in the arteries that carry blood from the heart to the lungs. 

Ambrisentan is usually taken orally once daily, with or without food. It's important to follow the prescribed dosage provided by your healthcare provider and to take the medication simultaneously each day to maintain consistent levels in your system. Swallow the tablet whole with water, and do not crush or chew it.

Ambrisentan may lead to common side effects such as headaches, nasal congestion, flushing, and peripheral edema (swelling in the arms, legs, hands, or feet). Serious side effects include liver problems, potential birth defects if taken during pregnancy, fluid retention that could worsen heart failure in certain individuals, and instances of anemia or decreased white blood cell counts.

Ambrisentan carries several important warnings. It can lead to liver problems, including elevated liver enzymes, necessitating regular liver function monitoring. The medication is contraindicated during pregnancy due to its potential to cause serious birth defects. It may cause fluid retention, possibly exacerbating heart failure in certain individuals, and has been associated with anemia and decreased white blood cell counts.

Ambrisentan's use should be approached with caution in those with lung conditions. It's advised to inform healthcare providers of all medications being taken, as drug interactions can occur, and lifestyle factors like alcohol consumption should be considered. Vision changes have been reported, and the potential for allergic reactions exists. It's essential to discuss these warnings with healthcare providers before using this medication ensuring its safe and appropriate use for individual patients.

Regular liver function tests are important due to the possibility of liver problems. The medication is contraindicated during pregnancy due to potential birth defects. Careful monitoring for fluid retention is crucial, particularly in those with a history of heart failure. Anemia and decreased white blood cell counts can warrant regular blood tests. Informing healthcare providers of all medications being taken is essential to prevent potential interactions. Lung conditions should be communicated, as the medication's benefits and risks need to be carefully assessed. Lifestyle factors like alcohol consumption and smoking should be discussed, and any vision changes should be promptly reported. Individuals must be aware of the potential for allergic reactions. 

1. Goodman & Gilman’s, The Pharmacological Basis of Therapeutics, Anti-arrhythmic drugs, 12th edition, 2011, 834.
2. Cipla EU Ltd, Electronic medicines compendium (EMC), [Revised on 16 Aug 2022] [ Accessed on 28th August 2023], https://www.medicines.org.uk/emc/product/11697/smpc#gref
3. Gilead Sciences,, US Food and Drug Administration, [Revised on November 2020], [Accessed on 28th August 2023],

The drug information on this page is not a substitute for medical advice, it is meant for educational purposes only. For further details, consult your doctor about your medical condition to know if you can receive this treatment.